Preferred Label : dipeptides;
MeSH definition : Peptides composed of two amino acid units.;
MeSH synonym : Dipeptide;
Wikipedia link : https://en.wikipedia.org/wiki/Dipeptide;
Is substance : O;
Origin ID : D004151;
UMLS CUI : C0012512;
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
- dipeptide [Artificial nutrition thesaurus concept]
Currated CISMeF NLP mapping
Indexing information
Record concept(s)
Related MeSH Supplementary Concept(s)
- A 62095 [MeSH Supplementary Concept]
- A 62198 [MeSH Supplementary Concept]
- AK 275 [MeSH Supplementary Concept]
- AK 295 [MeSH Supplementary Concept]
- AM2-97 [MeSH Supplementary Concept]
- CD10847 [MeSH Supplementary Concept]
- CH 1091 [MeSH Supplementary Concept]
- CH 248 [MeSH Supplementary Concept]
- CH 694 [MeSH Supplementary Concept]
- CI 992 [MeSH Supplementary Concept]
- CRC 220 [MeSH Supplementary Concept]
- DPLG3 [MeSH Supplementary Concept]
- DU 1777 [MeSH Supplementary Concept]
- EB148 [MeSH Supplementary Concept]
- ES 305 [MeSH Supplementary Concept]
- ES 6864 [MeSH Supplementary Concept]
- ES 8891 [MeSH Supplementary Concept]
- FK 888 [MeSH Supplementary Concept]
- GB-115 [MeSH Supplementary Concept]
- GT13072 [MeSH Supplementary Concept]
- GW 3333 [MeSH Supplementary Concept]
- GWL 78 [MeSH Supplementary Concept]
- JBP 923 [MeSH Supplementary Concept]
- JE 2147 [MeSH Supplementary Concept]
- JE 533 [MeSH Supplementary Concept]
- KBE009 [MeSH Supplementary Concept]
- KF33955 [MeSH Supplementary Concept]
- KK 3 [MeSH Supplementary Concept]
- KNI 577 [MeSH Supplementary Concept]
- LK 409 [MeSH Supplementary Concept]
- LK 410 [MeSH Supplementary Concept]
- LK 415 [MeSH Supplementary Concept]
- LK 517 [MeSH Supplementary Concept]
- MIV-247 [MeSH Supplementary Concept]
- MTC-220 [MeSH Supplementary Concept]
- P 34081 [MeSH Supplementary Concept]
- PP 35 [MeSH Supplementary Concept]
- PS 273 [MeSH Supplementary Concept]
- PTPD-12 [MeSH Supplementary Concept]
- PZL318 [MeSH Supplementary Concept]
- R-BC154 [MeSH Supplementary Concept]
- RB 106 [MeSH Supplementary Concept]
- RM 06 [MeSH Supplementary Concept]
- RMT5265 [MeSH Supplementary Concept]
- S 18523 [MeSH Supplementary Concept]
- S 2238 [MeSH Supplementary Concept]
- SFN 70 [MeSH Supplementary Concept]
- SI-591 [MeSH Supplementary Concept]
- SMI496 [MeSH Supplementary Concept]
- SP 5186 [MeSH Supplementary Concept]
- T-340 [MeSH Supplementary Concept]
- TMC 86A [MeSH Supplementary Concept]
- TMC 86B [MeSH Supplementary Concept]
- TMC 96 [MeSH Supplementary Concept]
- TP 300 [MeSH Supplementary Concept]
- TTL-315 [MeSH Supplementary Concept]
- TUB099 [MeSH Supplementary Concept]
- UK 101 [MeSH Supplementary Concept]
- WRR 182 [MeSH Supplementary Concept]
- WRR 183 [MeSH Supplementary Concept]
- alitame [MeSH Supplementary Concept]
- cn-716 [MeSH Supplementary Concept]
- glorin [MeSH Supplementary Concept]
- neotame [MeSH Supplementary Concept]
- no. 407 [MeSH Supplementary Concept]
- relacin [MeSH Supplementary Concept]
Semantic type(s)
UMLS correspondences (same concept)
Peptides composed of two amino acid units.
https://www.has-sante.fr/jcms/p_3283449/fr/komboglyze-metformine-/-saxagliptine
2021
false
false
false
France
evaluation of the transparency committee
saxagliptin
metformin
dipeptides
adamantane
metformin and saxagliptin
treatment outcome
insurance, health, reimbursement
drug combinations
Saxagliptin Hydrochloride
Metformin Hydrochloride
diabetes mellitus, type 2
hypoglycemic agents
drug therapy, combination
administration, oral
adult
incretins
dipeptidyl-peptidase iv inhibitors
---
https://www.has-sante.fr/jcms/p_3283452/fr/onglyza-saxagliptine-chlorhydrate-de
2021
false
false
false
France
evaluation of the transparency committee
saxagliptin
dipeptides
adamantane
treatment outcome
administration, oral
diabetes mellitus, type 2
Saxagliptin Hydrochloride
hypoglycemic agents
incretins
dipeptidyl-peptidase iv inhibitors
saxagliptin
drug therapy, combination
insurance, health, reimbursement
---
https://www.ema.europa.eu/en/medicines/human/EPAR/qtrilmet
2019
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
metformin
dapagliflozin
saxagliptin
Metformin Hydrochloride
Metformin Hydrochloride
hypoglycemic agents
hypoglycemic agents
drug approval
europe
metformin, saxagliptin and dapagliflozin
diabetes mellitus, type 2
adult
administration, oral
incretins
incretins
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Transporter 2 Inhibitors
Glycated Hemoglobin
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
dapagliflozin
metformin
dapagliflozin
saxagliptin
dapagliflozin
dipeptides
adamantane
glucosides
benzhydryl compounds
dapagliflozin
dipeptides
glucosides
benzhydryl compounds
---
https://www.has-sante.fr/portail/jcms/c_2890831/fr/naabak-naaxia-naaxiafree
2018
false
true
false
France
spaglumic acid
administration, ophthalmic
insurance, health, reimbursement
treatment outcome
evaluation of the transparency committee
naaxia
isospaglumic acid
dipeptides
---
https://www.ema.europa.eu/medicines/human/EPAR/qtern
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
drug combinations
dapagliflozin
dapagliflozin
saxagliptin and dapagliflozin
saxagliptin
saxagliptin
adult
diabetes mellitus, type 2
administration, oral
Sodium-Glucose transporter 2
incretins
incretins
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
dapagliflozin
glucosides
benzhydryl compounds
glucosides
benzhydryl compounds
dipeptides
adamantane
adamantane
dipeptides
adamantane
---
https://www.revmed.ch/RMS/2016/RMS-N-527/Combinaison-gliptine-gliflozine-dans-le-traitement-du-diabete-de-type-2
2016
false
false
false
Switzerland
French
journal article
diabetes mellitus, type 2
drug combinations
hypoglycemic agents
dipeptidyl-peptidase iv inhibitors
SGLT2 Inhibitor
treatment outcome
saxagliptin and dapagliflozin
dapagliflozin
saxagliptin
Linagliptin
linagliptin and empagliflozin
empagliflozin
Product containing empagliflozin and linagliptin (medicinal product)
administration, oral
Sodium-Glucose transporter 2
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
dipeptides
adamantane
adamantane
benzhydryl compounds
glucosides
---
http://www.has-sante.fr/portail/jcms/c_1782549/fr/komboglyze
http://www.has-sante.fr/portail/jcms/c_1782549/fr/komboglyze-saxagliptine/metformine-antidiabetique
2014
false
France
French
sulfonylurea compounds
Metformin Hydrochloride
Saxagliptin Hydrochloride
guidelines for drug use
evaluation of the transparency committee
drug combinations
saxagliptin
saxagliptin
metformin and saxagliptin
administration, oral
insurance, health, reimbursement
metformin
metformin
hypoglycemic agents
hypoglycemic agents
adult
diabetes mellitus, type 2
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
adamantane
dipeptides
aged
drug therapy, combination
dipeptides
dipeptides
---